British American Tobacco ADR shares climbed in mid-day trading, gaining roughly 2.7% to trade at $59.39 after the company published a first-half 2026 pre-close trading statement. The update reiterated the group's full-year guidance while offering a more upbeat projection for its next-generation product categories, commonly referred to as New Category products.
In the statement, management confirmed the group is on track to meet the lower end of its medium-term targets: revenue growth of 3% to 5% and adjusted profit growth of 4% to 6%. The company also increased its New Category revenue growth forecast for 2026 to the mid-teens, up from a previously stated expectation in the low double digits.
"We welcome the FDA’s recent prioritisation guidance as an important step toward effective enforcement and expanding market access for responsible products, and we are actively preparing our future Modern Oral and Vapour portfolio for market."
The timing of the trading statement coincided with a significant regulatory development. In May 2026 the U.S. Food and Drug Administration issued an enforcement discretion policy that allows certain unauthorized vapour products and nicotine pouches to remain on retail shelves while manufacturers' applications are under review. That represents a notable shift away from the prior requirement that products receive pre-authorization before they could be marketed.
Analysts have observed that the FDA's enforcement discretion approach tends to favour large, well-capitalized tobacco companies that possess the financial and regulatory bandwidth to progress through the application process. Market commentary singled out BAT’s Reynolds American subsidiary and its Vuse vapour brand as direct beneficiaries of the policy change.
Broker commentary ahead of the intraday move also supported sentiment. BofA Securities reiterated a Buy rating on BTI in the days leading up to the stock's advance, explicitly citing U.S. vapour performance as a positive catalyst.
At the same time, regulatory scrutiny remains present. Six Democratic senators wrote to Reynolds American and to Altria questioning lobbying activity related to the FDA policy shift. Those letters keep oversight and policymaker attention on the sector, although the outreach did not appear to materially curb investor enthusiasm during the trading session.
The broader U.S. equity market provided a contrasting backdrop. The S&P 500 fell about 1.5%, the Dow Jones Industrial Average declined roughly 0.7%, and the NASDAQ retreated near 2.5% on the same day. BTI’s share price advance ran counter to these indices and highlighted the defensive characteristics often attributed to tobacco stocks during risk-off market conditions, particularly when company-specific news is supportive.
Technical context may also have factored into buying interest. BTI's 52-week trading range runs from $46.38 to $67.30, indicating the stock remains below its high for the past year and providing potential upside for investors who view the company's updated outlook and regulatory tailwinds favorably.
Taken together, the company's encouraging pre-close trading update, the upgraded New Category growth forecast, a materially more permissive regulatory stance in the U.S. for vapour and nicotine pouch products, and continued analyst support created a supportive environment for BTI's outperformance. These elements allowed the stock to move decisively higher even as the wider market was retreating.